GH Research PLC is rated a Buy with $280.7M in cash, supporting lead candidate GH001 for Treatment-Resistant Depression. Read more on GHRS stock here.
As Medicare Advantage grows, first-time enrollees demonstrate increasing demographic and clinical diversity, indicating that benefits should be designed to reflect the population’s changing ...
Mayo Clinic researchers have developed a smartwatch-based alert system that signals parents at the earliest signs of a tantrum in children with emotional and behavioral disorders — prompting them to ...
Despite a pressing need to improve outcomes and address inequities in nursing homes, there is limited evidence about the specific factors required to successfully implement real-world interventions in ...
Device‑agnostic ePRO that is BYOD (bring your own device) with email/SMS reminders, patient portals, and unified reporting across EDC and eDiaries AUSTIN, TX / ACCESS Newswire / March 10, 2026 / ...
Cook Medical has picked Indiana University as one of its first iMRI Center of Excellence locations to advance MRI-guided medical interventions.
All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sitesPotential first and only pharmacological treatment for the most prominent neurologic ...
Morning Overview on MSN
Study suggests a daily multivitamin may slow biological aging
A randomized clinical trial involving 958 older adults suggests that taking a daily multivitamin for two years may produce a small, statistically significant slowdown in two measures of biological ...
Particle therapy experts gathered in London to discuss the transformative potential of laser-driven proton and ion beams ...
Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients to remain on drug CHAPEL HILL, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: ...
United Imaging, a global innovator in AI-powered advanced medical imaging technologies and intelligent healthcare ...
Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results